Caribou Biosciences (CRBU) said Sunday it initiated the phase 1 trial evaluating its experimental therapy, CB-010, in patients with lupus nephritis and extrarenal lupus.
Additionally, the company said it expects to report data from a study of CB-010 to treat certain large B cell lymphoma patients in the first half of 2025.
Pending confirmation of its human leukocyte antigen matching strategy, Caribou said it expects to launch a phase 3 trial for CB-010 in H2 2025.
Meanwhile, the company also expects to present dose escalation data from its cancer drug CB-011 in relapsed or refractory multiple myeloma in H1 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。